作者:
Bronwyn M,Gunn [1]
;
Vicky,Roy [1]
;
Marcus M,Karim [1]
;
Jessica N,Hartnett [2]
;
Todd J,Suscovich [1]
;
Augustine,Goba [3]
;
Mambu,Momoh [3]
;
John Demby,Sandi [4]
;
Lansana,Kanneh [3]
;
Kristian G,Andersen [3]
;
Jeffrey G,Shaffer [5]
;
John S,Schieffelin [6]
;
Robert F,Garry [7]
;
Donald S,Grant [2]
;
Galit,Alter [2]
作者单位:
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts.
[1]
Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana.
[2]
Viral Hemorrhagic Fever Program, Kenema Government Hospital.
[3]
Eastern Polytechnic University, Kenema, Sierra Leone.
[4]
Department of Immunology and Microbiology, Scripps Research Institute.
[5]
Scripps Research Translational Institute, La Jolla, California.
[6]
Department of Biostatistics and Bioinformatics, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana.
[7]
Ministry of Health and Sanitation, Freetown, Sierra Leone.
[8]
主题词
抗体, 中和(Antibodies, Neutralizing);抗体, 病毒(Antibodies, Viral);抗原, 病毒(Antigens, Viral);出血热, 埃博拉(Hemorrhagic Fever, Ebola);人类(Humans);免疫, 先天(Immunity, Innate);免疫球蛋白A(Immunoglobulin A);免疫球蛋白G(Immunoglobulin G);吞噬作用(Phagocytosis);塞拉利昂(Sierra Leone);幸存患者(Survivors)
DOI
10.1093/infdis/jiz364
PMID
31301137
发布时间
2020-08-03